Pharmaron, a fully integrated CRO offering laboratory and manufacturing services for pharmaceutical and biotech research and development, has acquired Quotient Bioresearch. Quotient, a U.K.-based CRO with more than 200 employees, focuses on integrating radiochemistry and metabolism. Part of this expertise is derived from Quotient’s previous acquisition of GE Amersham’s radiosynthesis business.
Integrated with Pharmaron’s broader technology platforms in chemistry, biology, DMPK, pharmacology, safety assessment, chemical and pharmaceutical development, this acquisition strengthens the company’s service portfolio, allowing it to provide more comprehensive and integrated services. The addition of the radiochemistry capabilities creates a global leading chemistry platform with a full spectrum of services. Further, the combined entity will generate greater market access in Asia, Europe and the U.S.
Dr. Boliang Lou, chairman and chief executive officer of Pharmaron, said, “This acquisition is part of our long-term strategy to grow our services and broaden our technical and geographic footprint to better serve clients throughout the world. Combining these two companies gives Pharmaron industry-leading custom radiosynthesis capabilities, and further consolidates our leading position in the field of discovery, preclinical and clinical DMPK. This move will help accelerate the discovery and development of novel drugs for our customers with Pharmaron’s comprehensive and integrated drug research and development engine.”
Stephen Lewinton, managing director of Quotient, said, “Quotient is focused on radiosynthesis and regulatory DMPK, particularly human clinical metabolism while Pharmaron has premier expertise in drug R&D services including discovery and preclinical safety and early phase DMPK. We are excited to become part of Pharmaron’s integrated drug research and development platform.”